Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Change in Cash: 2021-2025

Historic Change in Cash for ARS Pharmaceuticals (SPRY) over the last 5 years, with Sep 2025 value amounting to $8.0 million.

  • ARS Pharmaceuticals' Change in Cash rose 164.50% to $8.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.9 million, marking a year-over-year increase of 195.33%. This contributed to the annual value of -$20.2 million for FY2024, which is 85.56% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Change in Cash is $8.0 million, which was down 31.34% from $11.7 million recorded in Q2 2025.
  • ARS Pharmaceuticals' 5-year Change in Cash high stood at $173.2 million for Q4 2022, and its period low was -$122.7 million during Q1 2023.
  • In the last 3 years, ARS Pharmaceuticals' Change in Cash had a median value of $3.0 million in 2024 and averaged -$13.7 million.
  • The largest annual percentage gain for ARS Pharmaceuticals' Change in Cash in the last 5 years was 508.91% (2023), contrasted with its biggest fall of 1,461.70% (2023).
  • Over the past 5 years, ARS Pharmaceuticals' Change in Cash (Quarterly) stood at $121.5 million in 2021, then spiked by 42.61% to $173.2 million in 2022, then tumbled by 93.97% to $10.4 million in 2023, then rose by 6.91% to $11.2 million in 2024, then spiked by 164.50% to $8.0 million in 2025.
  • Its Change in Cash stands at $8.0 million for Q3 2025, versus $11.7 million for Q2 2025 and -$11.0 million for Q1 2025.